دورية أكاديمية
أعرض في EDS

EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.

التفاصيل البيبلوغرافية
العنوان: EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia.
المؤلفون: Charmsaz S; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia.; Department of Medicine, University of Queensland, Brisbane, QLD, Australia.; Department of Surgery, Royal College of Surgeons, Dublin, Ireland, UK., Al-Ejeh F; Personalised Medicine Team, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Yeadon TM; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Miller KJ; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Smith FM; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Stringer BW; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Moore AS; University of Queensland Diamantina Institute and UQ Child Health Research Centre, The University of Queensland, Brisbane, Australia, Oncology Service Children's Health Queensland Hospital and Health Service, Brisbane, QLD, Australia., Lee FT; Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Cooper LT; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Stylianou C; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia., Yarranton GT; KaloBios Pharmaceuticals Inc., Brisbane, CA, USA., Woronicz J; KaloBios Pharmaceuticals Inc., Brisbane, CA, USA., Scott AM; Olivia Newton-John Cancer Research Institute and School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia., Lackmann M; Department of Biochemistry and Molecular Biology, Monash University, Melbourne, VIC, Australia., Boyd AW; Leukaemia Foundation of Queensland Laboratory, QIMR-Berghofer Medical Research Institute, Brisbane, QLD, Australia.; Department of Medicine, University of Queensland, Brisbane, QLD, Australia.
المصدر: Leukemia [Leukemia] 2017 Aug; Vol. 31 (8), pp. 1779-1787. Date of Electronic Publication: 2016 Dec 06.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
أسماء مطبوعة: Publication: 2000- : London : Nature Publishing Group, Specialist Journals
Original Publication: [Baltimore, Md.] : Williams & Wilkins, [c1987-
مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy , Receptor, EphA3/*immunology, Animals ; Bismuth ; Cell Line, Tumor ; Humans ; Immunotherapy ; Mice ; Receptor, EphA3/metabolism ; Xenograft Model Antitumor Assays
مستخلص: The human EphA3 gene was discovered in a pre-B acute lymphoblastic leukemia (pre-B-ALL) using the EphA3-specific monoclonal antibody (mAb), IIIA4, which binds and activates both human and mouse EphA3. We use two models of human pre-B-ALL to examine EphA3 function, demonstrating effects on pre-B-cell receptor signaling. In therapeutic targeting studies, we demonstrated antitumor effects of the IIIA4 mAb in EphA3-expressing leukemic xenografts and no antitumor effect in the xenografts with no EphA3 expression providing evidence that EphA3 is a functional therapeutic target in pre-B-ALL. Here we show that the therapeutic effect of the anti-EphA3 antibody was greatly enhanced by adding an α-particle-emitting 213 Bismuth payload.
References: Cancer Inform. 2008;6:9-15. (PMID: 19259398)
Cell Stem Cell. 2012 Sep 7;11(3):359-72. (PMID: 22863534)
Cancer Cell. 2013 Feb 11;23(2):238-48. (PMID: 23410976)
Cold Spring Harb Perspect Biol. 2010 May;2(5):a001875. (PMID: 20452960)
Biochem Biophys Res Commun. 2002 Oct 18;298(1):87-94. (PMID: 12379224)
Expert Opin Drug Deliv. 2016;13(3):401-19. (PMID: 26654403)
Nat Rev Cancer. 2010 Mar;10(3):165-80. (PMID: 20179713)
Science. 2011 Jul 8;333(6039):228-33. (PMID: 21617041)
J Biol Chem. 1992 Feb 15;267(5):3262-7. (PMID: 1737782)
Leuk Lymphoma. 1999 Apr;33(3-4):371-6. (PMID: 10221518)
Leuk Res. 1992 Jun-Jul;16(6-7):655-63. (PMID: 1378917)
J Cell Biol. 2004 Mar 1;164(5):661-6. (PMID: 14993233)
Nature. 2015 May 21;521(7552):357-61. (PMID: 25799995)
Oncotarget. 2014 May 30;5(10):3145-58. (PMID: 24762669)
J Neurosci. 2004 Jul 14;24(28):6248-57. (PMID: 15254079)
Blood. 1999 Oct 1;94(7):2477-86. (PMID: 10498621)
Leuk Res. 2016 Nov;50:123-131. (PMID: 27736729)
Growth Factors. 2000;18(1):63-78. (PMID: 10831073)
Cancer Res. 2014 Aug 15;74(16):4470-81. (PMID: 25125683)
PLoS One. 2015 Jun 17;10(6):e0130692. (PMID: 26083390)
Int J Dev Biol. 2002;46(4):375-84. (PMID: 12141423)
Bioorg Med Chem. 1997 Oct;5(10):1925-34. (PMID: 9370037)
Cancer Res. 2005 Aug 1;65(15):6745-54. (PMID: 16061656)
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):50-3. (PMID: 21454190)
Nat Rev Drug Discov. 2014 Jan;13(1):39-62. (PMID: 24378802)
Nat Rev Mol Cell Biol. 2005 Jun;6(6):462-75. (PMID: 15928710)
Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1611-5. (PMID: 1311845)
New Biol. 1991 Aug;3(8):769-78. (PMID: 1657122)
Dev Cell. 2004 Oct;7(4):465-80. (PMID: 15469835)
Growth Factors. 2014 Dec;32(6):223-35. (PMID: 25413948)
Leukemia. 2016 Jun;30(6):1246-54. (PMID: 26847027)
المشرفين على المادة: 0 (Antibodies, Monoclonal)
EC 2.7.10.1 (Receptor, EphA3)
U015TT5I8H (Bismuth)
تواريخ الأحداث: Date Created: 20161207 Date Completed: 20171009 Latest Revision: 20181113
رمز التحديث: 20231215
DOI: 10.1038/leu.2016.371
PMID: 27922598
قاعدة البيانات: MEDLINE
الوصف
تدمد:1476-5551
DOI:10.1038/leu.2016.371